Featured Topics
Calendar

August 06, 2025

Q2 2025 Results / Quarterly Statement
Bayer Q2 Media Update

November 12, 2025

Q3 2025 Results / Quarterly Statement
Press Releases
Share Price / Index
June 03, 2025
Not intended for U.S. and UK Media
U.S. FDA approves third indication of Bayer blockbuster Nubeqa™ (darolutamide) for patients with advanced prostate cancer
June 02, 2025
Not intended for UK Media – Data from Phase III OASIS-4 study to be presented for the first time at 2025 ASCO Annual Meeting:
Elinzanetant significantly reduces frequency of moderate to severe vasomotor symptoms associated with endocrine therapy for breast cancer in Phase III OASIS-4 study
May 28, 2025
Not intended for U.S. and UK Media
Sevabertinib (BAY 2927088) granted FDA Priority Review for the treatment of patients with HER2-mutant non-small cell lung cancer

Our Products

Our broad product portfolio includes many world-famous brands that have shaped our Bayer brand. With our products, we are helping to find solutions to some of the greatest challenges of our time. So that health and nutrition can be made available to everyone.